News

A retrospective cohort study developed and validated a predictive model for IgA nephropathy, using routinely available variables.

In this episode, a panel of dermatologists join to discuss the impact of the Boards University educational initiative for residents and early-career physicians.

Zorrilla discusses the safety and efficacy of a series of minor surgeries in patients with hemophilia A/B currently taking fitusiran to control AT levels.

AASLD and AST have released 2 new guidelines on evaluating adult liver transplant candidates and managing non-graft complications after transplantation.

DBV Technologies announced that the phase 3 VITESSE trial on VIASKIN® Peanut patch for peanut-allergic children met its primary endpoint.

Sohail discusses the promising results from this retrospective cohort study which aims to put longstanding concerns about worsening infection to bed.

A meta-epidemiologic study highlights barriers to inclusion of older adults undergoing maintenance dialysis in randomized controlled trials.

Explore the latest advancements in diabetes technology, including updates on CGMs and insulin pumps, enhancing patient care and management.

Topline findings from the phase 2b REZOLVE-AA trial highlight the efficacy of rezpegaldesleukin in severe-to-very-severe alopecia areata.

GLP-1 medications are revolutionizing treatment for neurological conditions.

This December 16 episode features a discussion of winter skin concerns and seasonal dermatologic challenges impacting patients with skin of color.

Malec discusses the XTEND-ed trial, which proved the efficacy and tolerability of efanesoctocog alfa in adults and children with hemophilia A.

A review of 32 years of global data on FSGS highlights increased prevalence, with a limitation of biopsy variation and regional practices.

Pustake highlights the reticence with which clinicians should approach providing platelet transfusion to patients.

Study findings highlight the prevalence of steroid use in IBD care and identify key subgroups at higher risk of exposure.

Kereiakes discusses the potential of lerodalcibep for adults with hypercholesterolemia and high LDL-C, highlighting recent FDA approval.

New phase 3 data support the FDA approval of lumateperone, showing early efficacy and favorable tolerability as an adjunctive treatment for MDD.

Following the addition of a clinical study report to the NDA on December 12, the regulatory agency has extended the review period for the RASP inhibitor.

Investigators highlighted patterns of addictive behavior among those with chronic skin diseases in European tertiary dermatology centers.

Menopause care transforms with FDA-approved nonhormonal treatments, offering effective relief from hot flashes and improving quality of life for women.

Prurigo nodularis was shown to be linked with a significantly increased risk of malignancy, especially with cutaneous cancers.

Bomback, MD, MPH answers HCPLive’s questions regarding phase 3 VALIANT results and pegcetacoplan’s therapeutic ability in C3G and IC-MPGN.

Findings link GLP-1 RA use to reduced HCC risk in patients with type 2 diabetes, with benefits partly attributable to avoiding insulin's potential hepatotoxicity.

FibroGen’s oral HIF-PH inhibitor showed improved transfusion independence in high–high-transfusion-burden MDS patients in a post hoc phase 3 MATTERHORN analysis.

Vanda Pharmaceuticals submitted a BLA to the FDA for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP).

The Holly system is a first-of-its-kind implantable, continuous dialysis system designed to give patients freedom from the cycle of center-based dialysis.

Brenner describes shortcomings of pharmacologic CIC options and reviews real-world data on the Vibrant System’s benefits in this context.

FDA approves lerodalcibep, a groundbreaking PCSK9 inhibitor, offering a monthly injection for LDL cholesterol reduction in patients with HoFH.